PARP inhibitors too costly as maintenance therapy in ovarian cancer, says report

The Final Evidence Report issued by the Institute for Clinical and Economic Review (ICER) has recommended cutting the prices of PARP inhibitors if they are to provide value for money as maintenance therapy in ovarian cancer.

Payers and manufacturers should establish innovative payment mechanisms to seek affordability for patients, including outcomes-based contracting, ICER recommends.

The final recommendations echo the findings of an earlier ICER report, which also referred to prices being "out of alignment with the potential benefit they provide to patients".